NeoGenomics Laboratories, Inc. (NEO)
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
$17.38-0.46%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
QuarterlyIQ Insights · NEO
Next print, the company's guidance track record, and the earnings events we've seen in the last few years.
Likelihood the company beats analyst consensus on its next print. Read from its own beat history plus how sector peers have been reporting. Not a price-direction call: a serial beater often has the beat already priced in.
Prints it beat consensus, recent quarters.
Indicative, not a guarantee. Base rate ~71%.
Industry peers that beat since this name last reported.
Management's most recent EPS guidance action.
expected = 0.35*own_median(15.7) + peer(0.2*6.5) + term(0.0) → 6.8% (capped ±15.0)
in 50 days
Average absolute move on past earnings days.
Annualized: recent baseline volatility.
Of the last 0 guided quarters.
Actual vs. guided EPS, signed.
Excess return vs. sector ETF, day after print.
Earnings prints and pre-announcements detected in the SEC filing stream.
Results of Operations and Financial Condition. On July 28, 2026, NeoGenomics, Inc. issued a press release reporting its results for its second fiscal quarter of 2026. The press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and it shall not be deemed inco…
Quarterly EPS and revenue actuals vs. consensus across the last eight quarters (including beat/miss size and the forward consensus heading into the next print) are on the way.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Results of Operations and Financial Condition. On April 28, 2026, NeoGenomics, Inc. issued a press release reporting its results for its first fiscal quarter of 2026. The press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and it shall not be deemed inco…
Results of Operations and Financial Condition. On February 17, 2026 , NeoGenomics, Inc. issued a press release reporting its results for its fourth fiscal quarter of 2025 and full year ended December 31, 2025. The press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of th…
Results of Operations and Financial Condition. On January 12, 2026, NeoGenomics, Inc. (the “Company”) issued a press release announcing select preliminary unaudited financial results for the fourth quarter and fiscal year ended December 31, 2025, consisting of preliminary revenue, as well as the planned transition of Mr. Sherman from the role of Chief Financial Officer and the appointment of Abhishek Jain as the Company’s Executive Vice President, Finance. The selected financial results are b…
Results of Operations and Financial Condition. On October 28, 2025, NeoGenomics, Inc. issued a press release reporting its results for its third fiscal quarter of 2025. The press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and it shall not be deemed in…
Results of Operations and Financial Condition. On July 29, 2025, NeoGenomics, Inc. issued a press release reporting its results for its second fiscal quarter of 2025. The press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and it shall not be deemed inco…
Results of Operations and Financial Condition. On April 29, 2025, NeoGenomics, Inc. issued a press release reporting its results for its first fiscal quarter of 2025. The press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and it shall not be deemed inco…
Results of Operations and Financial Condition. On February 18, 2025 , NeoGenomics, Inc. issued a press release reporting its results for its fourth fiscal quarter of 2024 and full year ended December 31, 2024. The press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of th…
Results of Operations and Financial Condition. On November 5, 2024, NeoGenomics, Inc. issued a press release reporting its results for its third fiscal quarter of 2024. The press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and it shall not be deemed in…
Results of Operations and Financial Condition. On July 29, 2024, NeoGenomics, Inc. issued a press release reporting its results for its second fiscal quarter of 2024. The press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and it shall not be deemed inco…
Results of Operations and Financial Condition. On April 30, 2024 , NeoGenomics, Inc. issued a press release reporting its results for its first fiscal quarter of 2024. The press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and it shall not be deemed inc…